- Report
- January 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 180 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1214EUR$1,250USD£1,047GBP
- Report
- January 2022
- 200 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- January 2022
- 60 Pages
Global
From €3836EUR$3,950USD£3,310GBP
- Drug Pipelines
- June 2020
- 64 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- February 2024
- 108 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Report
- January 2021
- 132 Pages
Global
From €4371EUR$4,500USD£3,770GBP
The Keloid Drug market is a subset of the Dermatological Drugs market, which includes drugs used to treat skin conditions. Keloid Drugs are used to treat keloid scars, which are raised, thickened scars that form after a wound has healed. These drugs are typically administered topically or injected directly into the scar tissue. Commonly used Keloid Drugs include corticosteroids, 5-fluorouracil, and imiquimod.
Keloid Drugs are used to reduce the size of the scar, flatten it, and reduce the redness and itching associated with the scar. In some cases, the drugs can also help to prevent the formation of new keloid scars.
Some companies in the Keloid Drug market include Allergan, Galderma, and Merz Pharmaceuticals. Show Less Read more
